YAKUGAKU ZASSHI - JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, published by the Pharmaceutical Society of Japan, is a key academic journal dedicated to advancing the field of pharmaceutical sciences. Established in 1961 and set to contribute until 2024, this journal publishes original research articles, reviews, and clinical studies that encompass a wide spectrum of topics within pharmacology, toxicology, and pharmaceutics. Although the journal operates under a traditional subscription model, it maintains a recognized reputation with an impact factor that is steadily aligned within its category quartiles—ranking Q3 in Pharmaceutical Science and Q4 in Pharmacology as of 2023. With Scopus rankings reflecting its competitive standing, YAKUGAKU ZASSHI serves as a vital resource for researchers, professionals, and students looking to engage with innovative findings and broaden their understanding of pharmaceutical methodologies and research practices. With a current focus on bridging scientific research with real-world applications, it seeks to foster collaboration and knowledge sharing within the pharmaceutical community.

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.

Therapeutic Delivery is a prestigious journal dedicated to advancing the field of Pharmaceutical Science, published by Newlands Press Ltd. Since its inception in 2010, this journal has become a vital resource for researchers and professionals alike, focusing on innovative drug delivery systems and therapeutic approaches that enhance patient care. With an impressive impact factor reflective of its credibility and scholarly influence, Therapeutic Delivery is currently ranked in the Q2 quartile and placed at Rank #64 out of 183 in the realm of Pharmacology, Toxicology, and Pharmaceutics, showcasing its prominence in the field. The journal operates with an Open Access format, ensuring that groundbreaking research is readily available to a global audience. Based in the United Kingdom, it publishes comprehensive articles that cover a wide spectrum of topics within pharmaceutical sciences, from molecular mechanisms to clinical applications, thus catering to both academic and professional readerships. Researchers, students, and industry professionals will find Therapeutic Delivery an invaluable platform for sharing insights and fostering advancements in therapeutic methodologies.

The Journal of Drug Delivery Science and Technology, published by Elsevier, stands at the forefront of pharmaceutical research, focusing on innovative drug delivery systems and technologies. With a robust impact factor reflected in its Q1 rating within the pharmaceutical sciences category, this journal is recognized for its high-quality contributions, ranking #30 out of 183 in the Scopus pharmacology and toxicology category (2023). Since its inception in 2004, the journal has been pivotal in disseminating groundbreaking research and advancements in drug formulation and delivery methodologies. Researchers and practitioners alike benefit from its comprehensive articles, which are accessible under open access options, ensuring widespread dissemination of knowledge. As it converges towards its 20th anniversary in 2024, the journal continues to enhance its impact on the scientific community, paving the way for future innovations in drug delivery.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS is an esteemed academic journal published by BEGELL HOUSE INC, focusing on the innovative field of drug delivery systems and therapeutic carriers. With an ISSN of 0743-4863 and E-ISSN 2162-660X, this journal serves as a pivotal resource for researchers, professionals, and students engaged in pharmaceutical sciences and pharmacology. Spanning from 1984 to 2024, it has sustained its relevance in an evolving landscape, holding a commendable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science, as well as a Q3 ranking in Pharmacology for 2023. The journal is well-regarded for its critical and comprehensive reviews that enhance understanding and drive advancements in therapeutic applications. Access options are variable, providing insights into contemporary practices and innovations that shape drug delivery strategies. With a strong emphasis on interdisciplinary approaches, CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS not only fosters scholarly dialogue but also propels forward the critical field of therapeutic delivery, making it a valuable asset for anyone looking to deepen their knowledge and influence within this dynamic area of study.

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

MOLECULAR PHARMACEUTICS, published by the American Chemical Society, stands as a pivotal journal within the fields of Drug Discovery, Molecular Medicine, and Pharmaceutical Science, as evidenced by its impressive rankings in various categories, including Q1 in Drug Discovery and Pharmaceutical Science. With an ISSN of 1543-8384 and an E-ISSN of 1543-8392, this journal has been at the forefront of research since its inception in 2004 and continues to foster innovation and collaboration among researchers, professionals, and students well into 2024. The journal is noted for its significant impact, having achieved a Scopus ranking of #31 in Pharmaceutical Science and #36 in Drug Discovery, placing it in the top percentiles of the respective fields. While it currently does not offer Open Access, MOLECULAR PHARMACEUTICS remains an essential resource for advancing the understanding of molecular mechanisms in drug development and therapeutic strategies, ensuring that cutting-edge findings reach a wide audience and contribute to the progression of pharmaceutical sciences.

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

Journal of Reports in Pharmaceutical Sciences is a pivotal publication in the realm of pharmaceutical research, disseminating innovative findings that cater to the evolving landscape of pharmacology, toxicology, and biomedical engineering. Published by Wolters Kluwer Medknow Publications, the journal serves as a bridge for scholars and practitioners aiming to enhance their understanding of drug development, therapeutic advances, and biopharmaceutical technologies. With an ISSN of 2322-1232 and E-ISSN 2322-5106, it has established its relevance from 2012 to 2022, occupying notable quartile rankings, including Q3 in Pharmacology, Toxicology, and Pharmaceutics. Despite being categorized in Q4 in some areas, the journal's commitment to quality research ensures it remains a respected platform for disseminating significant insights. Researchers, professionals, and students alike will find this journal an indispensable resource for staying updated on critical advancements in pharmaceutical sciences, making it a go-to source for impactful studies that shape industry practices and academic inquiries.